Match!

Growth Hormone Levels in ESRD Patients

Published on Nov 1, 2014in Seminars in Dialysis2.056
· DOI :10.1111/sdi.12278
Garland A. Campbell2
Estimated H-index: 2
(UVA: University of Virginia),
Warren K. Bolton13
Estimated H-index: 13
(UVA: University of Virginia)
Abstract
  • References (37)
  • Citations (1)
References37
Newest
#1Peter Kamenicky (French Institute of Health and Medical Research)H-Index: 22
#2Gherardo Mazziotti (University of Brescia)H-Index: 42
Last. Philippe Chanson (French Institute of Health and Medical Research)H-Index: 53
view all 5 authors...
Besides their growth-promoting properties, GH and IGF-1 regulate a broad spectrum of biological functions in several organs, including the kidney. This review focuses on the renal actions of GH and IGF-1, taking into account major advances in renal physiology and hormone biology made over the last 20 years, allowing us to move our understanding of GH/IGF-1 regulation of renal functions from a cellular to a molecular level. The main purpose of this review was to analyze how GH and IGF-1 regulate ...
69 CitationsSource
Results Univariate correlation analyses showed that CKD stage was highly, positively correlated with the levels of preprandial and postprandial DG and positively correlated with TNF-a, IL-6, leptin, and age. Multivariate partial-correlation analyses showed that CKD was independently associated with the proportion of preprandial and postprandial DG, whereas TNF-a, IL-6, leptin, insulin, and age were not independently associated with either. Geometric mean (GM) preprandial and postprandial AG were...
12 CitationsSource
#1Jan Frystyk (AU: Aarhus University)H-Index: 58
#2C.B. Djurhuus (Novo Nordisk)H-Index: 5
Last. John Christiansen (AU: Aarhus University)H-Index: 72
view all 6 authors...
BACKGROUND: End-stage renal failure (ESRF) patients demonstrate augmented growth hormone (GH) secretion, but normal insulin-like growth factor-I (IGF-I) concentrations, indicating a state of GH resistance. To test this hypothesis, we compared the IGF-I response with exogenous GH in haemodialysis patients and healthy controls, with special focus on free GH and bioactive IGF-I. METHODS: Ultrafiltered free GH and total GH were measured in serum collected hourly for 24 h at baseline and after 7 days...
5 CitationsSource
#1Vishal Gupta (Jaslok Hospital)H-Index: 8
#2Marilyn Lee (Khoo Teck Puat Hospital)H-Index: 1
Severe growth retardation (below the third percentile for height) is seen in up to one-third children with chronic kidney disease. It is thought to be multifactorial and despite optimal medical therapy most children are unable to reach their normal height. Under-nutrition, anemia, vitamin D deficiency with secondary hyperparathyroidism, metabolic acidosis, hyperphosphatemia, renal osteodystrophy; abnormalities in the growth hormone/insulin like growth factor system and sex steroids, all have bee...
9 CitationsSource
#1Joel D. Kopple (UCLA: University of California, Los Angeles)H-Index: 85
#2Alfred K. Cheung (UofU: University of Utah)H-Index: 55
Last. Talat Alp Ikizler (VUMC: Vanderbilt University Medical Center)H-Index: 25
view all 10 authors...
Background. Adult maintenance hemodialysis (MHD) patients experience high mortality and morbidity and poor quality of life (QoL). Markers of protein-energy wasting are associated with these poor outcomes. The OPPORTUNITY� Trial examined whether recombinant human growth hormone (hGH) reduces mortality in hypoalbuminemic MHD patients. Secondary end points were effects on number of hospitalizations, cardiovascular events, lean body mass (LBM), serum proteins, exercise capacity, QoL and adverse even...
25 CitationsSource
The results of the largest, double-blind, placebo-controlled, multicentre, multinational randomized clinical trial (RCT) evaluating the effects of human growth hormone (hGH) on clinical outcome in 695 haemodialysed adults are published in this issue [1]. Designed to answer the important question whether hGH therapy might improve the notoriously poor survival in patients on dialysis, the OPPORTUNITY trial will enter the collective memory of the nephrology community as a paradigmatic case illustra...
4 CitationsSource
#1Ralf Nass (UVA: University of Virginia)H-Index: 18
#2Bruce D. Gaylinn (UVA: University of Virginia)H-Index: 26
Last. Michael O. Thorner (UVA: University of Virginia)H-Index: 71
view all 3 authors...
In humans, growth hormone (GH) is secreted from the anterior pituitary in a pulsatile pattern. The traditional view is that this secretory pattern is driven by two counter regulatory neurohormones, GHRH and somatostatin. Ghrelin, the natural ligand for the growth hormone (GH)-secretagogue receptor (GHS-R), is produced in the stomach. Ghrelin is the strongest GH secretagogue known to date, but the role of endogenous ghrelin in the regulation of circulating GH levels remains controversial. The fol...
29 CitationsSource
#1Victoria S. Lim (Roy J. and Lucille A. Carver College of Medicine)H-Index: 27
Niemczyk et al. treated predialysis chronic kidney disease patients with a new growth hormone-releasing hormone agonist, AKL-0707, and noted important changes in body composition characterized by an increase in fat-free mass, a modest rise in bone mineral content, and a reduction in fat mass. These changes were accompanied by a reduction in both serum urea nitrogen and normalized protein nitrogen appearance rate, while dietary protein intake was unchanged. Importantly, there were no serious adve...
1 CitationsSource
#1Martin Bidlingmaier (LMU: Ludwig Maximilian University of Munich)H-Index: 53
Disorders affecting GH secretion – either GH deficiency or GH excess (acromegaly) – are biochemically defined through peak or nadir concentrations of human GH in response to dynamic tests. Immunoassays employing polyclonal or monoclonal antibodies are routinely used for the analysis of GH concentrations, and many different assays are available on the market today. Unfortunately, the actual value reported for the GH concentration in a specific patient’s sample to a large extent depends on the ass...
38 CitationsSource
#1Ralf NassH-Index: 18
#2Suzan S. PezzoliH-Index: 22
Last. Michael O. ThornerH-Index: 71
view all 10 authors...
Background: Growth hormone secretion and muscle mass decline from midpuberty throughout life, culminating in sarcopenia, frailty, decreased function, and loss of independence. The decline of growth hormone in the development of sarcopenia is one of many factors, and its etiologic role needs to be demonstrated. Objective: To determine whether MK-677, an oral ghrelin mimetic, increases growth hormone secretion into the young-adult range without serious adverse effects, prevents the decline of fat-...
180 CitationsSource
Cited By1
Newest
Alberta has implemented the Specified Gas Emitters Regulation to address the issue of growing greenhouse gas emissions. The regulation allows large emitting facilities to achieve emission reduction targets using market‐based compliance instruments. The goal of this analysis is twofold: (1) Overview market participants, composition, and offset management approaches and (2) discuss future corporate offset strategy options. Market participants are generally weighted toward firms in the electricity ...
Source